Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQST NASDAQ:KYTX NASDAQ:TLRY OTCMKTS:VXRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$3.95-2.4%$4.24$2.93▼$7.55$493.72M1.453.09 million shs1.36 million shsKYTXKyverna Therapeutics$7.82-1.6%$8.67$2.80▼$13.67$475.80M1.87946,798 shs783,827 shsTLRYTilray Brands$4.40+0.3%$5.00$4.20▼$23.20$512.24M1.894.23 million shs2.40 million shsVXRTVaxart$0.56+0.9%$0.61$0.31▼$0.84$134.78M1.09586,213 shs78,248 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics-0.49%-6.70%-3.12%-4.72%+0.25%KYTXKyverna Therapeutics+2.19%-17.98%-1.49%-15.53%+80.87%TLRYTilray Brands-1.79%+1.62%-12.05%-36.98%-33.31%VXRTVaxart+1.46%-0.05%-1.79%-20.41%+32.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$3.95-2.4%$4.24$2.93▼$7.55$493.72M1.453.09 million shs1.36 million shsKYTXKyverna Therapeutics$7.82-1.6%$8.67$2.80▼$13.67$475.80M1.87946,798 shs783,827 shsTLRYTilray Brands$4.40+0.3%$5.00$4.20▼$23.20$512.24M1.894.23 million shs2.40 million shsVXRTVaxart$0.56+0.9%$0.61$0.31▼$0.84$134.78M1.09586,213 shs78,248 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics-0.49%-6.70%-3.12%-4.72%+0.25%KYTXKyverna Therapeutics+2.19%-17.98%-1.49%-15.53%+80.87%TLRYTilray Brands-1.79%+1.62%-12.05%-36.98%-33.31%VXRTVaxart+1.46%-0.05%-1.79%-20.41%+32.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$8.50115.46% UpsideKYTXKyverna Therapeutics 2.67Moderate Buy$30.00283.88% UpsideTLRYTilray Brands 2.25Hold$11.00150.28% UpsideVXRTVaxart 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest VXRT, AQST, KYTX, and TLRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2026TLRYTilray Brands TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $5.007/9/2026VXRTVaxart Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/24/2026KYTXKyverna Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/3/2026KYTXKyverna Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.005/15/2026KYTXKyverna Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $25.005/13/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026KYTXKyverna Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$30.00 ➝ $29.004/29/2026TLRYTilray Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026AQSTAquestive Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$8.004/23/2026KYTXKyverna Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.004/20/2026AQSTAquestive Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$44.54M11.11N/AN/A($0.28) per share-14.09KYTXKyverna TherapeuticsN/AN/AN/AN/A$3.85 per shareN/ATLRYTilray Brands$821.31M0.62$1.42 per share3.09$14.04 per share0.31VXRTVaxart$237.26M0.57$0.10 per share5.29$0.37 per share1.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$83.78M-$0.61N/AN/AN/A-137.08%N/A-49.33%8/10/2026 (Estimated)KYTXKyverna Therapeutics-$161.31M-$3.28N/AN/AN/AN/A-81.88%-64.87%8/11/2026 (Estimated)TLRYTilray Brands-$2.19B-$13.65N/AN/AN/A-156.51%-3.31%-2.42%7/28/2026 (Estimated)VXRTVaxart$16.33M$0.153.70N/AN/A14.51%61.43%20.07%8/12/2026 (Estimated)Latest VXRT, AQST, KYTX, and TLRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2026Q2 2026VXRTVaxart-$0.21N/AN/AN/A$1.93 millionN/A8/11/2026Q2 2026KYTXKyverna Therapeutics-$0.67N/AN/AN/AN/AN/A8/10/2026Q2 2026AQSTAquestive Therapeutics-$0.10N/AN/AN/A$11.42 millionN/A7/28/2026Q4 2026TLRYTilray Brands-$0.01N/AN/AN/A$249.64 millionN/A5/13/2026Q1 2026AQSTAquestive Therapeutics-$0.14-$0.07+$0.07-$0.07$10.90 million$14.45 million5/12/2026Q1 2026KYTXKyverna Therapeutics-$0.75-$0.66+$0.09-$0.66N/AN/A5/7/2026Q1 2026VXRTVaxart$0.02$0.02N/A$0.02$50.50 million$39.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A4.103.85KYTXKyverna Therapeutics0.138.158.15TLRYTilray Brands0.192.791.66VXRTVaxartN/A1.711.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%KYTXKyverna Therapeutics18.08%TLRYTilray Brands9.35%VXRTVaxart18.05%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics6.81%KYTXKyverna Therapeutics17.60%TLRYTilray Brands0.84%VXRTVaxart2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics160125.47 million116.92 millionOptionableKYTXKyverna Therapeutics9660.79 million50.10 millionOptionableTLRYTilray Brands2,842116.55 million115.57 millionOptionableVXRTVaxart120242.84 million236.04 millionNo DataVXRT, AQST, KYTX, and TLRY HeadlinesRecent News About These CompaniesVaxart (OTCMKTS:VXRT) Stock Rating Upgraded by Zacks ResearchJuly 11, 2026 | marketbeat.comVaxart (OTCMKTS:VXRT) Share Price Passes Below 200 Day Moving Average - Here's What HappenedJuly 10, 2026 | marketbeat.comVaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 VaccineJuly 6, 2026 | finance.yahoo.comVaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 VaccineJuly 6, 2026 | globenewswire.comVaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance EnhancementsJuly 1, 2026 | finance.yahoo.comVaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance EnhancementsJuly 1, 2026 | globenewswire.comVaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAYJune 27, 2026 | markets.businessinsider.comVaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAYJune 26, 2026 | globenewswire.comVaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine TrialJune 25, 2026 | finance.yahoo.comVaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine TrialJune 25, 2026 | globenewswire.comVaxart’s Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual MeetingJune 16, 2026 | finance.yahoo.comVaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual MeetingJune 16, 2026 | globenewswire.comVaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech ForumJune 15, 2026 | finance.yahoo.comVaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech ForumJune 15, 2026 | globenewswire.comVaxart to Participate in BTIG Infectious Disease Day 2026June 9, 2026 | finance.yahoo.comVaxart to Participate in BTIG Infectious Disease Day 2026June 9, 2026 | globenewswire.comVaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAYJune 8, 2026 | finance.yahoo.comVaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAYJune 8, 2026 | globenewswire.comVaxart Files Definitive Proxy Statement and Mails Letter to ShareholdersJune 1, 2026 | globenewswire.comVaxart Files Preliminary Proxy Statement and Issues Open Letter to ShareholdersMay 19, 2026 | finance.yahoo.comVaxart Files Preliminary Proxy Statement and Issues Open Letter to ShareholdersMay 19, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVXRT, AQST, KYTX, and TLRY Company DescriptionsAquestive Therapeutics NASDAQ:AQST$3.94 -0.10 (-2.35%) As of 01:42 PM Eastern This is a fair market value price provided by Massive. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Kyverna Therapeutics NASDAQ:KYTX$7.82 -0.13 (-1.57%) As of 01:42 PM Eastern This is a fair market value price provided by Massive. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Tilray Brands NASDAQ:TLRY$4.39 +0.02 (+0.34%) As of 01:42 PM Eastern This is a fair market value price provided by Massive. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.Vaxart OTCMKTS:VXRT$0.56 +0.01 (+0.91%) As of 01:03 PM EasternVaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s AI Spending Question Looms Over Q2 Earnings 3 Small-Cap Stocks Trading Under $10 With Room to Run Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger 3 Gold Stocks Under $5 With Massive Upside CleanSpark Inks a $6.6B AI Lease to Become a Digital Landlord Tower Semiconductor’s AI Rally Is Built on a Light-Speed Bet Blueprint for a Billion: Nebius Group Secures the AI Floor Marriott vs. Viking: Why the Better Quarter Doesn't Mean the Better Decade Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
